DNA sequencing market– the market is all set to cruise to a high altitude following plans by major healthcare players to employ Artificial intelligence into their platforms.

Pune, India, 2023 /press release/- Market Research Future (MRFR) has published a cooked research report on the “DNA Sequencing Market” that contains information from 2018 to 2030.

Market Highlights

The global DNA Sequencing Market is accounted to register a CAGR of 11.20% during the forecast period and is estimated to reach USD 4.8 billion by 2030.

The DNA sequencing market refers to the industry that encompasses the technologies, products, and services related to DNA sequencing, which is the process of determining the order of nucleotides (A, T, C, and G) in a DNA molecule. DNA sequencing has revolutionized various fields, including genomics, personalized medicine, drug discovery, agriculture, forensics, and more. The market for DNA sequencing has experienced significant growth over the years, driven by advancements in sequencing technologies, declining costs, and increasing applications.

Key Players

MRFR recognizes the following companies as the key players in the global DNA Sequencing Market — Agilent Technologies Inc., Thermo Fisher Scientific Inc., Illumina Inc., QIAGEN, F. Hoffmann-La Roche Ltd., Oxford Nanopore Technologies Ltd., Macrogen Inc., Perkin Elmer Inc., Pacific Biosciences of California Inc., and BGI. 

Segment Analysis

The global DNA Sequencing Market has been segmented based on Product, Application, and end user.

Based on Product, the market segments of DNA Sequencing include Consumables, Instruments, and Service. The consumable segment held the majority share in 2022, contributing most of the DNA Sequencing market revenue. The wide availability of reagents and kits for all library construction steps, such as DNA fragmentation, enrichment, adapter ligation, amplification, and quality control, contributes to a larger share of this segment. Most of these tools feature streamlined and simplified workflows, ready-to-use components, and compatibility with low-input and formalin-fixed specimens. 

The DNA Sequencing market segmentation has been divided based on Technology into Semiconductor Sequencing, Sequencing by Ligation, and Pyrosequencing. Sequencing by ligation accounted for the largest market share of the DNA Sequencing due to the widespread use of DNA sequencing platforms in sequencing scenarios. It is likely to continue to dominate throughout the forecast period. 

Based on End-User, the DNA Sequencing industry has been segmented into academic & government research institutes, pharmaceutical companies, biotechnology companies, and hospitals & clinics. The academic & government research institute segment is expected to contribute a higher market share due to the wide acceptance of Sanger techniques and NGS in academic and institutional research projects. Moreover, rising funding and investment plans increase these entities' demand for DNA sequencing products, leading to a more significant revenue share. 

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of DNA Sequencing Market Research Report

Regional Analysis

The global DNA Sequencing Market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North American DNA Sequencing market, which accounted for USD 1.05 billion in 2022, is expected to exhibit a significant CAGR growth during the study period. Continuous technological development by major players, high investment in R&D, and availability of technologically advanced healthcare infrastructure have led North America to hold a leading market share in the DNA sequencing. Several government initiatives in the United States and Canada support drug development and cancer treatment research. Further, the significant countries studied in the market report are The U.S., Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil. 

Europe's DNA Sequencing market accounts for the second-largest market share. Increasing adoption of organic growth strategies, such as product launches by key players in the Region to expand product portfolios, is expected to drive market growth over the forecast period. For example, in December 2021, Swiss-based pharmaceutical company F. Hoffmann-La Roche Ltd announced the launch of the AVENIO Edge System to provide a fully automated, integrated sequencing solution. The AVENIO Edge System is a pre-analytical platform for sequencing library preparation, target enrichment, and quantification steps that provides integrated end-to-end control and reliable, consistently high-quality results. Further, the German market of DNA Sequencing held the largest market share, and the U.K. market of DNA Sequencing was the fastest-growing market in the European Region. 

The Asia-Pacific DNA Sequencing Market is expected to grow at the fastest CAGR from 2022 to 2030. A growing customer base drives international companies to expand their business through strategic moves. A prominent California company has raised over $75 million to expand its desktop DNA sequencers to support the ongoing crisis of COVID-19. Moreover, the China market of DNA Sequencing held the largest market share, and the Indian market of DNA Sequencing was the fastest-growing market in the Asia-Pacific region. 

Key Findings of the Study

• The global DNA Sequencing Market is expected to reach USD 4.8 billion by 2030, at a CAGR of 11.20% during the forecast period.


• The Asia-Pacific DNA Sequencing Market is expected to grow at the fastest CAGR from 2022 to 2030. A growing customer base drives international companies to expand their business through strategic moves.


• Based on Product, the market segments of DNA Sequencing include Consumables, Instruments, and Service. The consumable segment held the majority share in 2022, contributing most of the DNA Sequencing market revenue.


• Agilent Technologies Inc., Thermo Fisher Scientific Inc., Illumina Inc., QIAGEN, F. Hoffmann-La Roche Ltd., Oxford Nanopore Technologies Ltd., Macrogen Inc., Perkin Elmer Inc., Pacific Biosciences of California Inc., and BGI.